A COMPUTATIONAL PATHOLOGY COMPANY
USING AI TO HELP PATHOLOGISTS IN THEIR DAILY ROUTINE
IDENTIFY.BIO HAS BUILT ITS FIRST AI ALGORITHM
"The Pap Smer Pre Screening Tool"
.png)
Used to pre-screen Liquid Based Cytology Pap smear specimens before diagnosis by the pathologist / cytotechnician as the case may be. The algorithm will flag cases suspicious for abnormalities such that the pathologist / cytotechnician would only need to examine 20% of the smears that were originally received at the lab The rest of the slides require no further review.
The algorithm would flag cases suspicious of containing squamous cell carcinoma or its pre-cursor lesions, adenocarcinoma and organisms like candida and bacterial vaginosis. These regions would be identified and the user would only have to look at these areas of abnormality and not the entire slide.
IN USA
50 Millon
Smears administrated annually
IN INDIA
1 Millon
Smears administrated annually
This large volume has made it burdensome for labs.
The Pap smear is the primary diagnostic test used to detect cervical cancer early in women. The volume has become so large that it is now becoming burdensome on labs to diagnose these smears in a timely manner, without impacting other parts of operations.
TECHNICAL SPECIFICATIONS
Intended User
Research use only
Image format
All OpenSlide formats
Specimen
Liquid Based Cytology Pap Smear
(ThinPrep and SurePath)
Input
Whole slide image of the Pap smear
Scanners we have tested with
Leica, Motic, Hamamatsu
Output: Review / No Review
(Whether or not the pathologist should review the slide)
OUR NEW PROCESS
LET US SAVE YOUR TIME!
OUR ALGORITHM SAVES UP TO 11 HOURS OF MANUAL EFFORT
PER 100 SLIDES
Time saving by implementing our Ai (for diagnosis + reporting):
EXISTING PROCESS
100 SLIDES
X
MIN / SLIDES
5 - 7
MINUTES
500 - 700
20 - 60
MINUTES
2 - 3
MIN / SLIDES
X
100 SLIDES
October 2023
Company Incorporation
October 2021
Clinical Evaluation of our Whole Slide Imaging Viewer complete
Feburary 2023
August 2023
2 Posters selected for presentation at PathVisions 2023
Obtained ISO 13485 Certificate for our Quality Management System
August 2023
MILESTONES
Submitted documentation for marketing approval in India
MEET THE TEAM
FOUNDERS
.jpg)
Rushabh Mehta
Co-founder; amp & CEO
Rushabh is the co-founder and CEO of identify.bio responsible for day-to-day operations of the company
Rushabh is the co-founder and CEO of identify.bio responsible for day-to-day operations of the company.
His past experience includes leading multi-disciplinary teams building big data and AI applications for leading global retailers and consumer brands.
He has an undergraduate degree from Babson College, MA, USA and an executive postgraduate degree in analytics and AI from IIM, Bangalore, India.
Rushabh Mehta
Founder & CEO
Akshay Daftary
Co-founder
Akshay currently serves as Director at SIRO Clinpharm, in charge of Global Business Development Activities and Operations.
Akshay currently serves as Director at SIRO Clinpharm, in charge of Global Business Development Activities and Operations. Akshay provides oversight, leadership, and guidance in the management of the company.He spent the first 4 years of his career at Bharat Serums and Vaccines. He then joined SIRO Clinpharm in 2018 to look after the Global Business Development and Operations.Akshay has an undergraduate degree in Economics and Mathematics from Emory University, GA, USA.
Akshay Daftare
Founder
SCIENTIFIC ADVISORY COMMITTEE
Dr. Girish Muzumdar
Dr. Girish Muzumdar (MD Pathology) serves as the Medical Director of identify.bio. He is also currently the Head of Surgical Pathology at the Bombay Hospital Institute of Medical Sciences. He has previously served as consultant Histopathologist to some of the largest central laboratories in India most recently at Suburban Diagnostics and earlier at Metropolis. Dr. Muzumdar was the Head of Surgical Pathology at the Asian Cancer Institute for 7 years. Dr. Muzumdar has published more than 30 research papers in reputed journals and has over 35 years of experience in surgical pathology and cytopathology.
Dr. Gautam Daftary
A medical doctor by qualification, Dr. Daftary is a second-generation entrepreneur with a successful record of accomplishment of starting various companies in the healthcare domain – from Diagnostics to Healthcare Delivery. He has founded several companies like Bharat Serums and Vaccines Private Limited, Siro Clinpharm Private limited and Aksigen Hospital Care, among several others. Some of the notable contributions from BSV are the equine biologicals for anti-toxins (anti snake venom serum) and anti-virals (anti-Rabies serum), nanotechnology-based Amphotericin emulsion for Kala Azar, and biotechnology-derived monoclonal Anti D in hemolytic disease of the newborn, monoclonal tetanus immunoglobulin for treatment of tetanus and Ulinastatin for treatment of sepsis and Acute Pancreatitis. Until divesting his equity stake in BSV to a large US-Based private equity firm, Dr. Daftary was primarily responsible for research and development, manufacturing and global sales in the organization Created a global scale research, development and manufacturing capabilities for cost effective and quality equine based anti-venoms and immunoglobulins biological product range Established a world-class Biotech research and manufacturing infrastructure with several first in the world products for specific life-threatening diseases. Pioneer in developing and commercialization novel drug delivery systems with several first-time products – globally and in India.
Dr. Nitin Gangane
Dr. Nitin Gangane (MD,DNB,FUICC,FICP,FAMS,Ph.D) is currently the Vice-Chancellor of Jawaharlal Nehru Medical College. He was previously the Dean of Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, Wardha, Maharashtra. He has been awarded Yamagiwa-Yoshida Memorial International Cancer Study Grant by UICC to work at International agency for research on cancer (WHO), Lyon, France and NIDCR/NIH, Bethesda, USA. He has also received Fellowship from Association of Nordic cancer society’s and the Indian Council of Medical research. He has more than 180 national and international publications to his credit. Dr. Gangane has been the Principal Investigator in seven research projects and co-investigator in 12 projects funded by international bodies like IARC (WHO), UICC, NIH, University of Umea and national funding agencies like ICMR, UGC, and DST. He has been a member of Governing Bodies such as Indian Council of Medical Research. He was also the Member of Management and Academic Council of Maharashtra University of Health Sciences. He has earlier worked on Senate of Maharashtra University of Health Sciences, Nashik, Maharashtra. He was the President of Maharashtra chapter of Indian Association of Pathologists and Microbiologists from 2006 to 2009
Dr. Anupama Gupta
Dr. Anupama Gupta is a professor and the Head of Department (Pathology) at the Mahatma Gandhi Institute of Medical Sciences, Sevagram, India. An alumnus of Gajra Raja Medical College, Gwalior, Dr Anupama obtained MD (Pathology) in 1994 and joined MGIMS as a lecturer in 1995. Trained in Oncopathology at Tata Memorial Hospital, Mumbai and keenly interested in Cytopathology, she was instrumental in establishing a flowcytometry laboratory in her department. Dr. Gupta has conducted and published more then 10 primary research projects. She is the Principal investigator for the ‘Population Based Cancer Registry’ in Wardha. It registers all the confirmed and suspected cases of cancer occurring in the Wardha district, including the incidence and mortality. It also follows all the patients of common cancers for compliance with treatment and the survival status.
MEDIA
identify.bio, a computational pathology company, today announced that it has been certified to the prestigious EN ISO 13485:2016 standard.
22 Aug 2023
ISO 13485 is a globally renowned standard that specifies requirements for a quality management system for medical devices including that of Software of a Medical Device (SaMD).